TheraRadar
Data updated: May 26, 2026

DERMABET (betamethasone valerate)

Dermatology Approved 1988-01-06

DERMABET is indicated for the treatment of Dermatoses.

Source: FDA Label • SUN PHARMA CANADA
1
Indication
--
Phase 3 Trials
38
Years on Market

Details

Status
Prescription
First Approved
1988-01-06
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: BETAMETHASONE VALERATE

DERMABET Approval History

1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
11 FDA actions from 1988 to 2017
Mar 2017 SUPPL
Label · Labeling
Sep 2004 SUPPL
Label · Labeling
Jul 2001 SUPPL
Mfg · Manufacturing (CMC)

What DERMABET Treats

1 indications

DERMABET is approved for 1 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dermatoses
Source: FDA Label

DERMABET Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DERMABET

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALA-SCALP
HYDROCORTISONE
1 shared
LEGACY PHARMA
Shared indications:
ALCLOMETASONE DIPROPIONATE
ALCLOMETASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
AMCINONIDE
AMCINONIDE
1 shared
TARO PHARM INDS
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05535738 STUDY00000321 Ph 2, Ph 3 active not recruiting Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
NCT04476420 2130520HBOM Ph 3 completed Comparative Effect of Nigella Sativa and Conventional Management for OSMF
NCT01646567 SHP-141C-002 Ph 1 completed SHP-141C in Plaque Type Psoriasis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DERMABET FDA Label Details

Indications & Usage

DERMABET is indicated for the treatment of Dermatoses.

Track DERMABET with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.